(Medical Xpress) -- Early in development, cells undergo a controlled demolition that helps to shape their raw, pliable material into the specialized forms they must have to do their jobs as adults. The process by which this ...
May 2, 2011
0
0
(Medical Xpress)—Clumps of α-synuclein protein in nerve cells are hallmarks of many degenerative brain diseases, most notably Parkinson's disease.
Mar 28, 2013
0
0
Altering the protein recycling complexes in human cells, including cancer cells, allows the cells to resist treatment with a class of drugs known as proteasome inhibitors, according to Whitehead Institute scientists.
Sep 2, 2015
0
77
An experimental drug that blocks the activation of an immune cell component effectively prevented rejection of heart transplants in mice, according to new research from scientists at Weill Cornell Medicine and Brigham and ...
Dec 13, 2016
0
113
In this issue of the Journal of Clinical Investigation, researchers led by Scott Pruitt at Duke University and Merck Research Laboratories report on a human clinical trial in which modified dendritic cells, a component of ...
Jun 24, 2013
0
0
Scientists of the Comprehensive Pneumology Center (CPC) at the Helmholtz Zentrum München have identified a new mechanism which contributes to the development of idiopathic pulmonary fibrosis (IPF). They showed that the pathological ...
Jul 27, 2015
0
9
De Bruin carries out chemical-biological research on proteasomes. 'They are a kind of degradation factory that cuts proteins in cells into smaller fragments. It's a highly useful activity: it's a way for cells to clean up ...
May 31, 2016
0
5
Part of the reason tuberculosis-causing bacteria are so good at colonizing the human body is that they have defenses against the body's immune system. A research team led by a Brown University chemist has developed a new ...
Dec 5, 2016
0
86
Misfolding and aggregation of normally soluble proteins are common pathological features of many neurodegenerative diseases, including Alzheimer's, Parkinson's, Creutzfeldt-Jacob and Huntington's diseases. For example, Parkinson's ...
Sep 29, 2020
0
5
(HealthDay)—For patients with multiple myeloma in whom treatment with lenalidomide and a proteasome inhibitor has failed, progression-free survival (PFS) is longer in those receiving the immunostimulatory monoclonal antibody ...
Nov 8, 2018
0
0
